Teplizumab Expands to Pediatric Stage 3 Type 1 Diabetes
FDA expanded teplizumab to ages 8–17 with newly diagnosed stage 3 type 1 diabetes, preserving insulin-producing beta-cell function when treatment begins within six weeks.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.